Die Arbeit analysiert anhand eines Fallbeispiels die finanziellen Fragen rund um die mögliche Markteinführung eines fiktiven pharmazeutischen Produktes.
Folgende Aspekte werden ausgeführt bzw. berechnet:
- Break even
- EBITDA / „Gewinn vor Zinsen, Steuern, Abschreibungen (auf Sachanlagen) und Abschreibungen (auf immaterielle Vermögensgegenstände)“
- Cash Flow / Geldfluss
- Internal Rate of Return / Interner Zinsfuß
- Net Present Value / Kapitalwert
- Investment Payback Period / Amortisationsdauer
- Sensitivitätsanalyse
Die Analyse erfolgt in Form eines fiktiven Berichts für die Leitung des Fallunternehmens.
Table of Contents
1. Introduction
2. Financial Analysis Citronex
2.1 Profitability
2.2 Capital Investment
2.3 Financial risk assessment
2.4 Additional Risk Considerations
3. Theoretical Framework
4. Conclusion
Appendix
Appendix A: Basic Information Repulse Travel Pharmaceuticals
Appendix A1: Company Information
Appendix A2: Citronex Product Information
Appendix A3: Financial Data for “Citronex”
Objectives and Topics
The primary objective of this report is to conduct a comprehensive financial appraisal for the introduction of a new pharmaceutical product, "Citronex," for Repulse Travel Pharmaceuticals (RTP). The analysis aims to determine the profitability and investment feasibility of the project by evaluating sales, cost, and investment data, while simultaneously addressing market risks and uncertainties.
- Profitability analysis including EBITDA, EBIT, and Break-even points.
- Capital investment appraisal using Payback Period, Net Present Value (NPV), and Internal Rate of Return (IRR).
- Sensitivity analysis of key parameters like demand volume, unit price, and discount rates.
- Qualitative assessment of internal and external business risks affecting long-term project viability.
Excerpt from the Book
2.1 Profitability
As RTP is a profitable company, it is clear that any new product will have to enhance or at least the company’s economic wealtIssue Therefore, an analysis of the cash flow as well as the profit for the projected life cycle is now being presented.
First the expected operating cash flow is calculated, including the fixed costs are directly linked to (non-)production of Citronex. With the financial information at hand, this figure also represents the EBITDA, a popular profitability indicator (Brigham, Houston 2007, P. 74). However, the cash outflow for the equipment purchase needs to be reflected in the cash flow calculation. On the other hand, equipment is an investment and thus has no direct affect to the income/profit statement (Downes, Goodman 2003). Therefore the following table separately displays EBITDA and undiscounted cash flow:
However, in order to fully reflect the cost of production, the loss in value for the equipment to be taken needs to be considered as a cost (Atrill, McLaney 2008) – in this case the depreciation for the necessary production equipment which is reflected in the following figure.
Summary of Chapters
1. Introduction: This chapter outlines the purpose of the report, which is to analyze the financial decision-making process for launching the new product "Citronex" at RTP.
2. Financial Analysis Citronex: This section provides a detailed quantitative evaluation of the product's profitability, capital investment requirements, financial risk via sensitivity analysis, and additional qualitative risk factors.
3. Theoretical Framework: This chapter critically reflects on the foundational financial techniques applied in the report and addresses their inherent limitations in decision-making support.
4. Conclusion: The concluding chapter summarizes the positive financial findings and recommends the introduction of Citronex, while highlighting key uncertainties that the board of RTP should consider.
Keywords
Corporate Finance, Investment Appraisal, Financial Analysis, Citronex, Profitability, Break-even, NPV, IRR, Sensitivity Analysis, Payback Period, Risk Assessment, WACC, Pharmaceutical Industry, Capital Budgeting, EBITDA.
Frequently Asked Questions
What is the core focus of this report?
The report focuses on evaluating the financial viability and investment attractiveness of introducing a new pharmaceutical product called "Citronex" for Repulse Travel Pharmaceuticals.
What are the central themes discussed?
The central themes include profitability metrics, capital investment appraisal, financial risk management, and the integration of qualitative factors into business decision-making.
What is the primary objective of the analysis?
The primary objective is to provide a sound, balanced recommendation to the board of RTP regarding whether or not to invest in the production and market launch of Citronex.
Which scientific methods are utilized?
The report employs standard financial management tools, including Break-even analysis, EBITDA calculation, Discounted Cash Flow (DCF), Net Present Value (NPV), Internal Rate of Return (IRR), and sensitivity analysis.
What is covered in the main section?
The main section details the quantitative calculations for profitability and capital investment, followed by a sensitivity analysis on price and demand, and a review of internal/external business risks.
Which keywords characterize this work?
Key terms include Corporate Finance, Investment Appraisal, Financial Analysis, Break-even point, IRR, NPV, and Sensitivity Analysis.
How does the author address the limitations of the techniques used?
The author discusses the theoretical limitations of tools like ARR and WACC in chapter 3, emphasizing that these quantitative methods should be combined with qualitative analysis for better decision-making.
What does the sensitivity analysis reveal about Citronex?
The analysis reveals that the project is sensitive to small changes; a deviation of approximately 1% in price or 5% in volume significantly impacts the IRR, though the project remains profitable until the break-even point.
- Quote paper
- Florian C. Kleemann (Author), 2010, Investment Appraisal and Financial Analysis, Munich, GRIN Verlag, https://www.grin.com/document/190094
